Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Incannex HealthcareIXHL -5.45%32 EV-to-OCF is 2.20 as of Jul. 26, 2026. GuruFocus rates IXHL with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Incannex Healthcare ranks better than 68.55% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Incannex Healthcare's Enterprise Value is $-39.04 Mil.
Incannex Healthcare's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-17.72 Mil. Therefore, Incannex Healthcare's EV-to-OCF for today is 2.20.
The historical rank and industry rank for Incannex Healthcare's EV-to-OCF or its related term are showing as below:
IXHL'
s EV-to-OCF Range Over the Past 10 Years
Min: -15.13 Med: -1.8 Max: 2.22
Current: 2.2
During the past 13 years, the highest EV-to-OCF of Incannex Healthcare was 2.22. The lowest was -15.13. And the median was -1.80.
IXHL's EV-to-OCF is ranked better than 68.55% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 10.565
vs IXHL: 2.20
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Incannex Healthcare's PE Ratio (TTM) for today is calculated as:
Incannex Healthcare's share price for today is $2.95.
Incannex Healthcare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.428.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Incannex Healthcare EV-to-OCF Related Terms
Incannex Healthcare EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Incannex Healthcare's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Incannex Healthcare's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Incannex Healthcare EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Incannex Healthcare's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Incannex Healthcare's EV-to-OCF falls into.
Incannex Healthcare's current Enterprise Value is $-39.04 Mil.
Incannex Healthcare's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Incannex Healthcare (IXHL) has a EV-to-OCF of 2.20 as of Jul. 26, 2026. According to the industry distribution chart, Incannex Healthcare ranks #317 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 31.4%.
Is Incannex Healthcare's EV-to-OCF too high?
Incannex Healthcare's current EV-to-OCF is 2.20. The Drug Manufacturers industry median EV-to-OCF is 10.57. Incannex Healthcare's value of 2.20 is 79.2% below this industry median. Based on the distribution chart, Incannex Healthcare ranks #317 out of 1008 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Incannex Healthcare has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Incannex Healthcare's EV-to-OCF compare to BTAI and SCYX?
According to the Drug Manufacturers industry distribution chart, Incannex Healthcare ranks #317 out of 1008 companies for EV-to-OCF. This puts Incannex Healthcare in the upper half of its industry. The industry median EV-to-OCF is 10.57. Incannex Healthcare's value of 2.20 is 79.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.57, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Incannex Healthcare's current EV-to-OCF of 2.20 is 79.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Incannex Healthcare's current EV-to-OCF is 2.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incannex Healthcare stock overvalued right now?
Incannex Healthcare (IXHL) has a current EV-to-OCF of 2.20. The current EV-to-OCF is 2.20 and 79.2% below the Drug Manufacturers industry median of 10.57. Incannex Healthcare's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Incannex Healthcare (IXHL), the current EV-to-OCF is 2.20 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
32GF Score
Get the complete analysis for IXHL
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IXHL has been successfully added to your 
